tipifarnib has been researched along with Leukemia in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS | 1 |
| Ahmed, TA; Hayslip, J; Leggas, M | 1 |
| Fujiwara, S; Nagai, T; Ohmine, K; Ozawa, K; Sakurai, C; Uesawa, M | 1 |
| Adamson, PC; Arceci, RJ; Balis, FM; Blaney, SM; Fox, E; Goodspeed, W; Goodwin, A; Jayaprakash, N; Widemann, BC; Wright, JJ; Zannikos, P | 1 |
| Abboud, CN; Lancet, JE; Liesveld, JL; Lu, C; McNair, C; Menon, A; Rosell, KE; Rosenblatt, JD | 1 |
| Flournoy, N; Paul, RK; Rosenberger, WF | 1 |
| Zhang, GS | 1 |
| Kano, Y; Komatsu, N; Miyoshi, T; Muroi, K; Nagai, T; Nakamura, M; Ohmine, K; Ozawa, K | 1 |
| Chen, W; Chow, A; Hayes, S; Perez-Ruixo, JJ; Zhang, S | 1 |
| Adjei, AA; End, DW; Karp, JE; Kaufmann, SH; Lancet, JE; Wright, JJ | 1 |
2 review(s) available for tipifarnib and Leukemia
| Article | Year |
|---|---|
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics | 2010 |
Current status of clinical trials of farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Leukemia; Neoplasms; Piperidines; Pyridines; Quinolones; Signal Transduction | 2001 |
2 trial(s) available for tipifarnib and Leukemia
| Article | Year |
|---|---|
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Farnesyltranstransferase; Female; Half-Life; Humans; Infant; Leukemia; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Quinolones | 2011 |
Exposure-toxicity relationships for tipifarnib in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Male; Middle Aged; Quinolones; Treatment Outcome | 2007 |
6 other study(ies) available for tipifarnib and Leukemia
| Article | Year |
|---|---|
Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukemia; Quinolones; ras Proteins; Simvastatin | 2014 |
Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leukemia; Quinolones; Signal Transduction; Sirolimus; Tumor Cells, Cultured | 2010 |
Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.
Topics: Alkyl and Aryl Transferases; Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Adhesion; Cell Cycle; Cell Movement; Colony-Forming Units Assay; Enzyme Inhibitors; Farnesyltranstransferase; Hematopoiesis; Humans; Leukemia; Mice; Mice, Inbred NOD; Mice, SCID; Poly(ADP-ribose) Polymerases; Quinolones; Time Factors; Tumor Cells, Cultured | 2003 |
Quantile estimation following non-parametric phase I clinical trials with ordinal response.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Computer Simulation; Data Interpretation, Statistical; Humans; Leukemia; Maximum Tolerated Dose; Quinolones; Regression Analysis; Statistics, Nonparametric | 2004 |
[New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].
Topics: Acute Disease; Antineoplastic Agents; Carbazoles; Furans; Humans; Indoles; Leukemia; Leukemia, Myeloid, Acute; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Quinolones; ras Proteins; Staurosporine | 2005 |
Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Cell Line, Tumor; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Quinolones | 2005 |